IPCA LABORATORIES LTD.
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹206.63 billion
- Book Value:
- Revenue TTM:
- ₹62.48 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹40.63 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
IPCA LABORATORIES LTD. had its IPO on under the ticker symbol IPCALAB.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. IPCA LABORATORIES LTD. has a staff strength of 16,167 employees.
Shares of IPCA LABORATORIES LTD. opened at ₹894.1 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹886.75 - ₹912.95, and closed at ₹896.55.
This is a -0.26% slip from the previous day's closing price.
A total volume of 8,153 shares were traded at the close of the day’s session.
In the last one week, shares of IPCA LABORATORIES LTD. have increased by +1.81%.
IPCA LABORATORIES LTD.'s Key Ratios
IPCA LABORATORIES LTD. has a market cap of ₹206.63 billion, indicating a price to book ratio of 3.7935 and a price to sales ratio of 3.7514.
In the last 12-months IPCA LABORATORIES LTD.’s revenue was ₹62.48 billion with a gross profit of ₹40.63 billion and an EBITDA of ₹9.46 billion. The EBITDA ratio measures IPCA LABORATORIES LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IPCA LABORATORIES LTD.’s operating margin was 11.26% while its return on assets stood at 5.41% with a return of equity of 8.36%.
In Q1, IPCA LABORATORIES LTD.’s quarterly earnings growth was a negative -41.1% while revenue growth was a positive 17.5%.
IPCA LABORATORIES LTD.’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹18.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IPCA LABORATORIES LTD.’s profitability.
IPCA LABORATORIES LTD. stock is trading at a EV to sales ratio of 3.6275 and a EV to EBITDA ratio of 18.5539. Its price to sales ratio in the trailing 12-months stood at 3.7514.
IPCA LABORATORIES LTD. stock pays annual dividends of ₹4 per share, indicating a yield of 0.5% and a payout ratio of 21.53%.
Balance sheet and cash flow metrics
- Total Assets
- ₹86.26 billion
- Total Liabilities
- ₹18.06 billion
- Operating Cash Flow
- Capital Expenditure
- ₹4.94 billion
- Dividend Payout Ratio
IPCA LABORATORIES LTD. ended 2023 with ₹86.26 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹86.26 billion while shareholder equity stood at ₹58.42 billion.
IPCA LABORATORIES LTD. ended 2023 with ₹0 in deferred long-term liabilities, ₹18.06 billion in other current liabilities, 253700000.00 in common stock, ₹58.17 billion in retained earnings and ₹381.40 million in goodwill. Its cash balance stood at ₹12.58 billion and cash and short-term investments were ₹22.75 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹6.52 billion.
IPCA LABORATORIES LTD.’s total current assets stands at ₹51.89 billion while long-term investments were ₹0 and short-term investments were ₹4.22 billion. Its net receivables were ₹9.89 billion compared to accounts payable of ₹5.25 billion and inventory worth ₹17.43 billion.
In 2023, IPCA LABORATORIES LTD.'s operating cash flow was ₹-7250000000.00 while its capital expenditure stood at ₹4.94 billion.
Comparatively, IPCA LABORATORIES LTD. paid ₹0.22 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
IPCA LABORATORIES LTD. stock is currently trading at ₹896.55 per share. It touched a 52-week high of ₹1028.7404 and a 52-week low of ₹1028.7404. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹850.62 and 200-day moving average was ₹811.48 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4666.3% of the company’s stock are held by insiders while 4068.2% are held by institutions.
Frequently Asked Questions About IPCA LABORATORIES LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.